EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Electrophysiologic effects clinical efficacy and safety of intravenous and oral nadolol in refractory supraventricular tachyarrhythmias


American Journal of Cardiology 59(4): 307-312
Electrophysiologic effects clinical efficacy and safety of intravenous and oral nadolol in refractory supraventricular tachyarrhythmias
The electrocardiographic and electrophysiologic effects, clinical efficacy and safety of intravenous and oral nadolol therapy were examined in 34 patients with recurrent supraventricular tachyarrhythmias (SVT) undergoing electrophysiologic evaluation. Programmed electrical stimulation was performed in the control (drug-free) state, after infusion of intravenous nadolol (mean dose 0.09 .+-. 0.03 mg/kg) and chronic oral nadolol therapy in patients who responded to intravenous nadolol (mean dose 83 .+-. 12 mg for 5 days). Intravenous nadolol administration prolonged mean sinus cycle length (p = 0.009), mean PR interval (p = 0.001) and mean AH interval (p = 0.001), with no significant electrophysiologic effects in the atrium, ventricle or accessory bypass tracts. Oral nadolol had similar electrocardiographic and electrophysiologic effects, but of lesser magnitude. Intravenous nadolol resulted in complete suppression of induced SVT in 78% of patients with sinus and atrioventricular nodal reentrant tachycardia and 11% of patients with atrioventricular (AV) reentrant tachycardia (p < 0.001). Partial responses were frequent in intraatrial or AV reentrant tachycardia (37%). Oral nadolol suppressed induction of SVT in patients who responded to intravenous nadolol. Adverse reactions to intravenous and oral nadolol were infrequent.sbd.6% and 8%, respectively.sbd.and usually did not require drug withdrawal. Intravenous nadolol is highly effective in sinus and AV nodal reentrant tachycardia, and a successful electrophysiologic response to it predicts efficacy of long-term oral nadolol therapy. It has limited efficacy alone in AV reentrant tachycardia and should be considered in combination with other antiarrhythmic therapy in this type of SVT.

Accession: 005349281

PMID: 3812280

DOI: 10.1016/0002-9149(87)90804-6

Download PDF Full Text: Electrophysiologic effects clinical efficacy and safety of intravenous and oral nadolol in refractory supraventricular tachyarrhythmias



Related references

Efficacy and safety of intravenous and oral nadolol for supraventricular tachycardia in children. Journal of the American College of Cardiology 19(3): 630-635, 1992

Clinical efficacy and electrophysiologic effects of intravenous and oral encainide in patients with accessory atrioventricular pathways and supraventricular arrhythmias. American Journal of Cardiology 54(6): 544-549, 1984

Clinical efficacy and safety of intravenous esmolol in the treatment of supraventricular tachyarrhythmias: Multiple centers analysis of 309 cases. Zhonghua Xinxueguanbing Zazhi 24(6): 404-407, 1996

Efficacy and safety of intravenous nadolol for supraventricular tachycardia. American Journal of Cardiology 60(6): 59d-62d, 1987

Efficacy, safety, and tolerance of d-sotalol in patients with refractory supraventricular tachyarrhythmias. American Heart Journal 117(3): 562-568, 1989

Intravenous sotalol for the treatment of supraventricular tachyarrhythmias safety and efficacy. Journal of the American College of Cardiology 19(3 SUPPL A): 220A, 1992

Safety and efficacy of intravenous sotalol in terminating supraventricular tachyarrhythmias. Journal of the American College of Cardiology 17(2 SUPPL A): 56A, 1991

Efficacy and safety of short intravenous amiodarone in supraventricular tachyarrhythmias. International Journal of Cardiology 35(1): 77-85, 1992

Low-dose intravenous diltiazem--efficacy and safety in supraventricular tachyarrhythmias. Indian Heart Journal 48(4): 365-367, 1996

Electrophysiologic effects of intravenous E-4031, a novel class III antiarrhythmic agent, in patients with supraventricular tachyarrhythmias. Journal of Cardiovascular Pharmacology 23(3): 374-378, 1994